CCL13 and breast cancer: BC-fortified infants showed higher levels of monocyte chemoattractant protein 4 (MCP-4 or CCL13) and IFN-γ inducible protein-10 (IP-10 or CXCL10) 1 and 2 weeks after the start of fortification.